Is the metabolic syndrome a real clinical entity and should it receive drug treatment? (Q36640581)

15 August 2017

1 reference

title

Is the metabolic syndrome a real clinical entity and should it receive drug treatment? (English)

1 reference

15 August 2017

1 reference

Tamara Darsow

1

0 references

author name string

David Kendall

series ordinal

2

1 reference

PubMed ID

17076996

15 August 2017

David Maggs

series ordinal

3

1 reference

15 August 2017

1 November 2006

1 reference

15 August 2017

Current diabetes report

1 reference

15 August 2017

6

1 reference

15 August 2017

5

1 reference

15 August 2017

357-364

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-006-0006-y

15 August 2017

0 references

cites work

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11892-006-0006-Y

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11892-006-0006-Y

Meta-analysis: surgical treatment of obesity

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11892-006-0006-Y

Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes

21 January 2018

1 reference

12 December 2020

Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes

1 reference

12 December 2020

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

12 December 2020

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Food for thought: endocannabinoid modulation of lipogenesis

1 reference

12 December 2020

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change

1 reference

12 December 2020

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

12 December 2020

Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data

1 reference

12 December 2020

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?

1 reference

12 December 2020

Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome

1 reference

12 December 2020

Hyperleptinemia: protecting the heart from lipid overload

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

12 December 2020

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

12 December 2020

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

1 reference

12 December 2020

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

12 December 2020

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

12 December 2020

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

12 December 2020

Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors

1 reference

12 December 2020

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

12 December 2020

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.

1 reference

12 December 2020

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

12 December 2020

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

12 December 2020

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study

1 reference

12 December 2020

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

12 December 2020

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

1 reference

12 December 2020

A comparison of the prevalence of the metabolic syndrome using two proposed definitions

1 reference

12 December 2020

Lifestyle behaviors associated with lower risk of having the metabolic syndrome

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

12 December 2020

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

1 reference

12 December 2020

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

1 reference

12 December 2020

Bariatric surgery: a systematic review and meta-analysis

1 reference

12 December 2020

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

12 December 2020

The metabolic syndrome: requiescat in pace

1 reference

12 December 2020

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

12 December 2020

Fat as an endocrine organ: relationship to the metabolic syndrome.

1 reference

12 December 2020

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

12 December 2020

Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials

1 reference

12 December 2020

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

1 reference

12 December 2020

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

12 December 2020

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

1 reference

12 December 2020

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

12 December 2020

The metabolic syndrome: prevalence, CHD risk, and treatment

1 reference

12 December 2020

Glitazones: clinical effects and molecular mechanisms

1 reference

12 December 2020

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

12 December 2020

Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020

Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease

1 reference

12 December 2020

10.1007/S11892-006-0006-Y

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17076996